Show simple item record

dc.contributor.authorWeber, A
dc.contributor.authorButterweck, H
dc.contributor.authorMais-Paul, U
dc.contributor.authorTeschner, W
dc.contributor.authorLei, L
dc.contributor.authorMuchitsch, E-M
dc.contributor.authorKolarich, D
dc.contributor.authorAltmann, F
dc.contributor.authorEhrlich, HJ
dc.contributor.authorSchwarz, HP
dc.date.accessioned2017-06-13T00:27:11Z
dc.date.available2017-06-13T00:27:11Z
dc.date.issued2011
dc.identifier.issn0042-9007
dc.identifier.doi10.1111/j.1423-0410.2010.01415.x
dc.identifier.urihttp://hdl.handle.net/10072/339697
dc.description.abstractBackground and Objectives:  A human plasma-derived butyrylcholinesterase preparation manufactured on the industrial scale is described. Material and Methods:  The human butyrylcholinesterase (hBChE) product was extensively investigated for its purity using immunological and electrophoretic methods and characterized by thorough glycoproteomic approaches. A comprehensive preclinical testing programme addressing safety and pharmacokinetic parameters supplemented the biochemical characterization. Results:  The high-purity hBChE preparation is tetrameric and has high specific activity and molecular integrity of the protein backbone. Acute toxicity studies and in vivo thrombogenicity studies provided evidence of a sufficient safety margin for use in humans. Conclusion:  Extensive preclinical safety and pharmacokinetic testing confirmed that this hBChE preparation can be used for further efficacy testing as a bioscavenger for toxic organophosphate compounds in appropriate animal models and ultimately in humans.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherWiley-Blackwell Publishing
dc.relation.ispartofpagefrom285
dc.relation.ispartofpageto297
dc.relation.ispartofissue3
dc.relation.ispartofjournalVox Sanguinis
dc.relation.ispartofvolume100
dc.subject.fieldofresearchClinical Sciences not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchMedical Physiology
dc.subject.fieldofresearchcode110399
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1116
dc.titleBiochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorKolarich, Daniel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record